Hubert Humphrey and Bladder Cancer: A Plain-Language Look

Eleven years, three chapters

Hubert Humphrey served as a senator from Minnesota and as vice president of the United States. His cancer ran alongside most of that career.

MinnPost reports what happened in June 1967. Exploratory surgery for a urinary problem turned up a malignant tumor on his bladder. Surgeons removed it. He believed he had been cured. The cancer came back in 1973, and he went through a series of radiation treatments. By 1976 it had spread, and his bladder was removed. He died on January 13, 1978, at his Minnesota home, at the age of 66.

The pattern in that timeline is not unique to him. Bladder cancer is a disease that returns. It is managed over years, not settled in a season. That is the single most useful thing to understand about it.

What the lining does, and what goes wrong

The bladder is a hollow muscle that holds urine until you release it. Its inner surface is lined with urothelium. That layer of cells stretches as the bladder fills and shrinks as it empties.

Almost all bladder cancer starts in that lining. The National Cancer Institute states that "more than 90% of bladder cancers are transitional cell carcinomas," a type now more often called urothelial carcinoma. Squamous cell carcinoma and adenocarcinoma of the bladder exist, but they are uncommon.

Smoking is the dominant cause. NCI states flatly that "cigarette smoking causes up to one-half of all bladder cancers." It raises risk two to four times. Chemicals from tobacco are filtered by the kidneys and then sit in the bladder in concentrated form. NCI also names occupational chemical exposures, previous chemotherapy, and chronic infections as risk factors.

The signal is blood

NCI puts it in one line: "The most common symptom is blood in the urine, called hematuria." Sometimes it is visible and turns the urine pink, red, or cola-colored. Sometimes it is microscopic and shows up only on a urine test.

NCI also lists frequent urination and pain or burning while urinating. Two more are urinating often at night, and feeling a need to go when the bladder is not full. Those overlap almost exactly with a urinary tract infection. That is why bladder cancer is sometimes treated as an infection first.

The tell is what happens next. An infection responds to antibiotics and stays gone. Bleeding that recurs, or symptoms that keep coming back after treatment, need a different explanation.

When to get checked

• Any visible blood in the urine, even once, even painless, even if it clears the next day
• Blood found on a routine urine test, which should be followed up rather than filed away
• Burning, urgency, or frequency that returns repeatedly after antibiotics
• Getting up several times a night to urinate when that is new for you
• Being unable to urinate at all, which is an emergency
• One-sided lower back pain, bone pain, swelling in the feet, or unexplained weight loss

Painless bleeding is the version people most often ignore. It is also the classic presentation, and it deserves the same urgency as bleeding that hurts.

Why the diagnosis needs a camera

Scans are not enough here. NCI states that "when bladder cancer is suspected, the most useful diagnostic test is cystoscopy." It notes that CT and ultrasound lack the sensitivity to rule it out.

Cystoscopy means passing a thin lighted scope through the urethra to look directly at the bladder wall. If something suspicious appears, the next step is a transurethral resection. The tumor is shaved out through the same route and sent to pathology. NCI adds that this is usually combined with an examination under anesthesia.

The line that divides this disease

Underneath the lining lies the detrusor, the muscle that squeezes the bladder empty. Whether the cancer has reached that muscle is the question everything else follows from.

NCI describes non-muscle-invasive disease as often treatable by removing the tumors through the urethra. Muscle-invasive disease, it says, "is much more likely to spread to other parts."

The proportions are encouraging. NCI reports that roughly 70 to 80 percent of people present with superficial tumors. It adds an important pairing. Low-grade bladder cancer "often recurs in the bladder after treatment but rarely invades the muscular wall." Meanwhile "almost all deaths from bladder cancer result from high-grade disease." Grade and invasion, not the word cancer by itself, carry the weight.

Treatment on each side of that line

For non-muscle-invasive disease, NCI describes transurethral resection first. Chemotherapy is then placed directly into the bladder, and after that comes either BCG or surveillance. BCG is a bacterial preparation instilled through a catheter that provokes an immune reaction against remaining tumor cells.

For muscle-invasive disease, NCI describes "neoadjuvant multiagent cisplatin-based chemotherapy followed by radical cystectomy." Neoadjuvant means the chemotherapy comes first, before surgery. Radical cystectomy removes the bladder. That requires a new route for urine, either a stoma on the abdomen or a reservoir built from bowel. NCI notes an alternative. Radiation therapy given with concurrent chemotherapy can preserve the bladder in selected patients.

Ask about that alternative by name if it matters to you. It is not right for everyone, but it is a real option rather than a consolation prize.

Living with surveillance

Low-grade tumors recur readily. Follow-up cystoscopy on a schedule is part of the disease, not an optional extra. NCI notes that tests used for diagnosis and staging are repeated to track how treatment is working.

That schedule is a burden. It is also what keeps recurrences small and treatable. Missing appointments is the most common way a manageable situation stops being one.

What the numbers show

The 2026 projection of 84,530 new bladder cancer cases and 17,870 deaths in the United States comes from the American Cancer Society, and SEER, NCI's cancer surveillance program, reports it. NCI's own counting gives the rate of new cases as 17.9 per 100,000 people per year and the median age at diagnosis as 73.

Five-year relative survival across all stages is 79.1 percent, from cases diagnosed between 2016 and 2022. By stage, SEER lists 98.0 percent for in situ disease, 73.0 percent for localized, 41.8 percent for regional, and 9.6 percent once the cancer has reached distant sites. Half of all cases are caught in situ.

These are population figures, shaped heavily by how early the bleeding was investigated. They describe a group, not a person.

Sources

• https://www.minnpost.com/politics-policy/2011/05/final-chapter-hubert-humphrey-returns-public-life/
• https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq
• https://www.cancer.gov/types/bladder/symptoms
• https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq
• https://seer.cancer.gov/statfacts/html/urinb.html